The strong first-year Ryoncil revenue validates commercial execution and supports the pipeline expansion into larger indications (adult SR-aGvHD, DMD, CLBP, LVAD). Traders should watch for enrollment updates in the adult SR-aGvHD trial and the DMD trial, as well as the CLBP Phase 3 data readout and the modular BLA review for rexlemestrocel-L. The CAR technology license adds optionality in autoimmune indications but is early-stage.
Price Chart
Executive Summary
Mesoblast reported Ryoncil net revenue of US$36M for Q4 FY2026 and US$115M for the first full year post-FDA approval, with US$103M cash at quarter end. Operational milestones include commencement of the adult SR-aGvHD label extension trial, IND clearance for Duchenne muscular dystrophy, and achievement of the 300-patient enrollment target in the pivotal Phase 3 chronic low back pain trial. The company also received a BLA filing number for rexlemestrocel-L in LVAD patients and acquired a CAR technology license.
Key Facts
- Ryoncil net revenue Q4 FY2026: US$36 million
- Ryoncil net revenue first full year post-FDA approval: US$115 million (US$66.5M in H2)
- Cash and cash equivalents at June 30, 2026: US$103 million
- Net operating cash spend full year: US$43.8 million (US$13.4M in H2)
- Registration trial for Ryoncil label extension into adults with SR-aGvHD commenced and enrolling
- FDA IND clearance received for Ryoncil in ambulatory children aged 5-9 with Duchenne muscular dystrophy
- Target of at least 300 patients treated in pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain achieved
- BLA filing number received from FDA for rexlemestrocel-L in prevention of GI bleeding in LVAD patients
- Acquired exclusive worldwide license to a patented CAR technology platform for MSC enhancement
Financial Impact
Ryoncil generated US$115M in annual net revenue in its first full launch year; operating cash burn of US$43.8M; cash position of US$103M provides ~11 quarters of runway at current burn rate
Risk Factors
- Clinical trial enrollment and data readout risks for adult SR-aGvHD, DMD, and CLBP trials
- Regulatory approval uncertainty for rexlemestrocel-L BLA in LVAD indication
- Competition from other cell therapies and biologics in inflammatory diseases
- Cash burn may require future financing if revenue growth slows or pipeline milestones are delayed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001345099-26-000072 |
| Document: form6-kxpressreleasecoverf.htm | 0001345099-26-000072 |
| Document: 0001345099-26-000072-index-headers.html | 0001345099-26-000072 |
| Document: 0001345099-26-000072-index.html | 0001345099-26-000072 |
| Document: 0001345099-26-000072.txt | 0001345099-26-000072 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 27, 2026 5w ago | 20-F | $18.18 $15.48 | ▼ −14.85% | ▼ −14.34% | $14.07 (−22.58%) |
Aug 27, 2026 5w ago | Press Release | $18.18 $15.48 | ▼ −14.85% | ▼ −14.34% | $14.07 (−22.58%) |
Aug 24, 2026 5w ago | 6-K | $16.64 $15.92 | ▼ −4.33% | ▼ −5.64% | $14.07 (−15.41%) |
Aug 17, 2026 6w ago | Press Release | $17.02 $14.74 | ▼ −13.40% | ▼ −11.42% | $14.07 (−17.30%) |
Jul 30, 2026 9w ago | 6-K | $14.55 $18.18 | ▲ +24.95% | ▲ +20.98% | $14.07 (−3.26%) |
Jul 14, 2026 11w ago | 6-K | $16.74 $16.92 | ▲ +1.08% | ▼ −1.42% | $14.07 (−15.92%) |
Jul 14, 2026 11w ago | Press Release | $16.74 $16.92 | ▲ +1.08% | ▼ −1.42% | $14.07 (−15.92%) |
Jul 10, 2026 12w ago | 6-K | $15.44 $15.94 | ▲ +3.24% | ▲ +0.81% | $14.07 (−8.84%) |
Jul 10, 2026 12w ago | Press Release | $15.44 $15.94 | ▲ +3.24% | ▲ +0.81% | $14.07 (−8.84%) |
Jul 1, 2026 13w ago | 6-K | $14.09 $14.13 | ▲ +0.28% | ▲ +2.47% | $14.07 (−0.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access